Contextual Considerations and Recommendations for Estimating the Value of Alzheimer’s Disease Therapies T. Joseph Mattingly IIR. Brett McQueenPei-Jung Lin Current Opinion 23 September 2021 Pages: 1101 - 1107
A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement Jihyung HongEun-Young Bae Review Article 28 July 2021 Pages: 1109 - 1121
Lack of Cost-Effectiveness of Preoperative Erythropoiesis-Stimulating Agents and/or Iron Therapy in Anaemic, Elective Surgery Patients: A Systematic Review and Updated Analysis Bert AvauHans Van RemoortelPhilippe Vandekerckhove Systematic Review Open access 08 July 2021 Pages: 1123 - 1139
Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson’s Disease: A Swedish Register-Based Study in 1823 Observations Jenny M. NorlinKlas KellerborgPer Odin Original Research Article 07 July 2021 Pages: 1141 - 1149
Valuing SF-6Dv2 in Australia Using an International Protocol Brendan MulhernRichard NormanJohn Brazier Original Research Article 12 July 2021 Pages: 1151 - 1162
Lifetime Costs for Treated Follicular Lymphoma Patients in the US Caitlin EichtenQiufei MaRichard T. Maziarz Original Research Article 17 July 2021 Pages: 1163 - 1183
State of the ART? Two New Tools for Risk Communication in Health Technology Assessments Sabine E. GrimmXavier PouwelsManuela A. Joore Original Research Article Open access 19 July 2021 Pages: 1185 - 1196
Deterministic Sensitivity Analysis Under Ignorance Afschin Gandjour Letter to the Editor Open access 15 September 2021 Pages: 1197 - 1198
Comment on “Deterministic Sensitivity Analysis Under Ignorance” Rick A. VremanJoost W GeenenWim G. Goettsch Letter to the Editor 15 September 2021 Pages: 1199 - 1199